Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jul 3;83(3):287–293. doi: 10.1054/bjoc.2000.1166

FDG–PET in the prediction of survival of patients with cancer of the pancreas: a pilot study

N R Maisey 1, A Webb 1, G D Flux 1, A Padhani 1, D C Cunningham 1, R J Ott 1, A Norman 1
PMCID: PMC2374572  PMID: 10917540

Abstract

Carcinoma of the pancreas is an aggressive tumour with an extremely poor prognosis. Recent studies have shown that chemotherapy can improve survival as well as quality of life. Since the prognosis is generally poor, the identification of early responders to chemotherapy is important to avoid unnecessary toxicity in patients who are not responding. Response assessment by conventional radiographic methods is problematical because treatment induces fibrosis and makes tumour measurements difficult. The aim of this pilot study was to assess 18-fluoro-deoxy-glucose positron emission tomography (FDG-PET) as an early marker of the benefit of chemotherapy. Eleven patients with histologically proven adenocarcinoma of the pancreas were treated with protracted venous infusional 5-fluorouracil (PVI 5-FU) alone or PVI 5-FU and mitomycin C (MMC). FDG-PET scans were performed prior to and at 1 month following the commencement of chemotherapy. FDG uptake was compared with the tumour dimensions measured on a computer tomographic (CT) scan. Patients were followed up for relapse, death and symptomatic response. Three of the 11 patients had no measurable FDG uptake prior to chemotherapy. Of the eight patients who had measurable uptake prior to treatment, seven had a reduction in uptake at 1 month. Six out of the 11 patients had no measurable FDG uptake at 1 month. The overall survival (OS) in these patients ranged from 124 to 1460 days, with a median of 318.5 days. This was superior in comparison to patients who had residual FDG uptake at 1 month (median survival 318.5 days vs 139 days;P = 0.034) and there was a trend to improved symptoms (84% [5/6] vs 20% [1/5];P = 0.13). There was no statistically significant correlation between best CT response and FDG uptake at 1 month. These results suggest that the absence of FDG uptake at 1 month following chemotherapy for carcinoma of the pancreas is an indicator of improved overall survival. This suggests that FDG-PET may be superior to response assessment by conventional radiographic methods and FDG-PET may have the potential to help make difficult treatment decisions in the management of pancreatic cancer. Larger prospective studies are required to confirm this finding. © 2000 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (249.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahuja V., Coleman R. E., Herndon J., Patz E. F., Jr The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998 Sep 1;83(5):918–924. [PubMed] [Google Scholar]
  2. Bares R., Klever P., Hauptmann S., Hellwig D., Fass J., Cremerius U., Schumpelick V., Mittermayer C., Büll U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994 Jul;192(1):79–86. doi: 10.1148/radiology.192.1.8208970. [DOI] [PubMed] [Google Scholar]
  3. Black R. J., Bray F., Ferlay J., Parkin D. M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997 Jun;33(7):1075–1107. doi: 10.1016/s0959-8049(96)00492-3. [DOI] [PubMed] [Google Scholar]
  4. Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. doi: 10.1200/JCO.1997.15.6.2403. [DOI] [PubMed] [Google Scholar]
  5. Findlay M., Young H., Cunningham D., Iveson A., Cronin B., Hickish T., Pratt B., Husband J., Flower M., Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996 Mar;14(3):700–708. doi: 10.1200/JCO.1996.14.3.700. [DOI] [PubMed] [Google Scholar]
  6. Glimelius B., Hoffman K., Sjödén P. O., Jacobsson G., Sellström H., Enander L. K., Linné T., Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996 Aug;7(6):593–600. doi: 10.1093/oxfordjournals.annonc.a010676. [DOI] [PubMed] [Google Scholar]
  7. Haberkorn U., Strauss L. G., Dimitrakopoulou A., Seiffert E., Oberdorfer F., Ziegler S., Reisser C., Doll J., Helus F., van Kaick G. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med. 1993 Jan;34(1):12–17. [PubMed] [Google Scholar]
  8. Higashi T., Sakahara H., Torizuka T., Nakamoto Y., Kanamori S., Hiraoka M., Imamura M., Nishimura Y., Tamaki N., Konishi J. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med. 1999 Sep;40(9):1424–1433. [PubMed] [Google Scholar]
  9. Higashi T., Tamaki N., Honda T., Torizuka T., Kimura T., Inokuma T., Ohshio G., Hosotani R., Imamura M., Konishi J. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997 Sep;38(9):1337–1344. [PubMed] [Google Scholar]
  10. Hoekstra O. S., Ossenkoppele G. J., Golding R., van Lingen A., Visser G. W., Teule G. J., Huijgens P. C. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993 Oct;34(10):1706–1710. [PubMed] [Google Scholar]
  11. Inokuma T., Tamaki N., Torizuka T., Fujita T., Magata Y., Yonekura Y., Ohshio G., Imamura M., Konishi J. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med. 1995 Feb;36(2):229–235. [PubMed] [Google Scholar]
  12. Marsden P. K., Ott R. J., Bateman J. E., Cherry S. R., Flower M. A., Webb S. The performance of a multiwire proportional chamber positron camera for clinical use. Phys Med Biol. 1989 Aug;34(8):1043–1062. doi: 10.1088/0031-9155/34/8/007. [DOI] [PubMed] [Google Scholar]
  13. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Minn H., Lapela M., Klemi P. J., Grénman R., Leskinen S., Lindholm P., Bergman J., Eronen E., Haaparanta M., Joensuu H. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997 Dec;38(12):1907–1911. [PubMed] [Google Scholar]
  15. Nakata B., Chung Y. S., Nishimura S., Nishihara T., Sakurai Y., Sawada T., Okamura T., Kawabe J., Ochi H., Sowa M. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997 Feb 15;79(4):695–699. [PubMed] [Google Scholar]
  16. Nicolson M., Webb A., Cunningham D., Norman A., O'Brien M., Hill A., Hickish T. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol. 1995 Oct;6(8):801–804. doi: 10.1093/oxfordjournals.annonc.a059319. [DOI] [PubMed] [Google Scholar]
  17. Okada J., Oonishi H., Yoshikawa K., Imaseki K., Uno K., Itami J., Arimizu N. FDG-PET for the evaluation of tumor viability after anticancer therapy. Ann Nucl Med. 1994 May;8(2):109–113. doi: 10.1007/BF03165015. [DOI] [PubMed] [Google Scholar]
  18. Okada J., Oonishi H., Yoshikawa K., Itami J., Uno K., Imaseki K., Arimizu N. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 1994 Aug;8(3):187–191. doi: 10.1007/BF03164996. [DOI] [PubMed] [Google Scholar]
  19. Okazumi S., Isono K., Enomoto K., Kikuchi T., Ozaki M., Yamamoto H., Hayashi H., Asano T., Ryu M. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992 Mar;33(3):333–339. [PubMed] [Google Scholar]
  20. Oshida M., Uno K., Suzuki M., Nagashima T., Hashimoto H., Yagata H., Shishikura T., Imazeki K., Nakajima N. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998 Jun 1;82(11):2227–2234. [PubMed] [Google Scholar]
  21. Palmer K. R., Kerr M., Knowles G., Cull A., Carter D. C., Leonard R. C. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994 Jun;81(6):882–885. doi: 10.1002/bjs.1800810629. [DOI] [PubMed] [Google Scholar]
  22. Price P., Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer. 1995 Nov;31A(12):1924–1927. doi: 10.1016/0959-8049(95)00421-1. [DOI] [PubMed] [Google Scholar]
  23. Prott F. J., Schönekaes K., Preusser P., Ostkamp K., Wagner W., Micke O., Pötter R., Sulkowski U., Rübe C., Berns T. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer. 1997;75(4):597–601. doi: 10.1038/bjc.1997.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Reske S. N., Grillenberger K. G., Glatting G., Port M., Hildebrandt M., Gansauge F., Beger H. G. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997 Sep;38(9):1344–1348. [PubMed] [Google Scholar]
  25. Rigo P., Paulus P., Kaschten B. J., Hustinx R., Bury T., Jerusalem G., Benoit T., Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996 Dec;23(12):1641–1674. doi: 10.1007/BF01249629. [DOI] [PubMed] [Google Scholar]
  26. Ross P., Norman A., Cunningham D., Webb A., Iveson T., Padhani A., Prendiville J., Watson M., Massey A., Popescu R. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol. 1997 Oct;8(10):995–1001. doi: 10.1023/a:1008263516099. [DOI] [PubMed] [Google Scholar]
  27. Stollfuss J. C., Glatting G., Friess H., Kocher F., Berger H. G., Reske S. N. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology. 1995 May;195(2):339–344. doi: 10.1148/radiology.195.2.7724750. [DOI] [PubMed] [Google Scholar]
  28. Strauss L. G. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996 Oct;23(10):1409–1415. doi: 10.1007/BF01367602. [DOI] [PubMed] [Google Scholar]
  29. Wittenberg J., Simeone J. F., Ferrucci J. T., Jr, Mueller P. R., vanSonnenberg E., Neff C. C. Non-focal enlargement in pancreatic carcinoma. Radiology. 1982 Jul;144(1):131–135. doi: 10.1148/radiology.144.1.7089244. [DOI] [PubMed] [Google Scholar]
  30. Zimny M., Bares R., Fass J., Adam G., Cremerius U., Dohmen B., Klever P., Sabri O., Schumpelick V., Buell U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med. 1997 Jun;24(6):678–682. doi: 10.1007/BF00841409. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES